Pieces of the Puzzle - A Multi-method Approach to Tumour Profiling
News Nov 07, 2014
Oxford Gene Technology (OGT) will present a workshop titled ‘An Integrated Genomic Approach to Tumor Profiling’ at the Association for Molecular Pathology (AMP) annual meeting on the 12-15th November at National Harbor, MD.
Research into the identification of clinically relevant genetic mutations is growing rapidly; however, the complexity of genomic variation means that the use of multiple technologies is often required to obtain a complete understanding of a given disease. James Clough, Executive Vice President Commercial, and Ephrem Chin, Business Development Manager at OGT, will explore how next generation sequencing (NGS), microarrays and fluorescence in situ hybridization (FISH) can be combined to present a fully comprehensive, integrated approach and meet this growing need.
As NGS becomes more affordable, targeted sequencing provides an accurate, high-resolution approach to mutation detection. Developed in collaboration with recognized cancer experts, OGT’s SureSeq™ Solid Tumour Panel covers all exons of key genes for a range of cancer types including breast, prostate, ovarian, lung and colorectal - enabling detection and discovery of both known and novel variants.
For detecting copy number variations (CNV), array comparative genomic hybridization (aCGH) is still the gold standard, and OGT’s CytoSure Cancer +SNP Arrays also provide the facility to uncover LOH information. For certain aberrations such as translocations, however, FISH remains the most reliable mainstream technology, being the final piece of this genomic puzzle explored in OGT’s workshop.
Attendees of the workshop on November 12th, at 2pm in Maryland Ballroom C, will hear how the latest genomic technologies are being applied together to comprehensively characterize genetic abnormalities for accelerating cancer research.
Delegates can also find out more about OGT’s comprehensive molecular genetics solutions at booth 207 and enter a competition for the chance to win a SureSeq™ Solid Tumour Panel, or myProbes™ Custom FISH Probe project.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE